Metabolomic signature of type 1 diabetes-induced sensory loss and nerve damage in diabetic neuropathy.
DPN
Hyperglycemia
Sensory neurons
Streptozotocin
TCA
Journal
Journal of molecular medicine (Berlin, Germany)
ISSN: 1432-1440
Titre abrégé: J Mol Med (Berl)
Pays: Germany
ID NLM: 9504370
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
received:
31
10
2018
accepted:
26
03
2019
revised:
24
03
2019
pubmed:
6
4
2019
medline:
20
6
2020
entrez:
6
4
2019
Statut:
ppublish
Résumé
Diabetic-induced peripheral neuropathy (DPN) is a highly complex and frequent diabetic late complication, which is manifested by prolonged hyperglycemia. However, the molecular mechanisms underlying the pathophysiology of nerve damage and sensory loss remain largely unclear. Recently, alteration in metabolic flux has gained attention as a basis for organ damage in diabetes; however, peripheral sensory neurons have not been adequately analyzed with respect to metabolic dysfunction. In the present study, we attempted to delineate the sequence of event occurring in alteration of metabolic pathways in relation to nerve damage and sensory loss. C57Bl6/j wild-type mice were analyzed longitudinally up to 22 weeks in the streptozotocin (STZ) model of type 1 diabetes. The progression of DPN was investigated by behavioral measurements of sensitivity to thermal and mechanical stimuli and quantitative morphological assessment of intraepidermal nerve fiber density. We employed a mass spectrometry-based screen to address alterations in levels of metabolites in peripheral sciatic nerve and amino acids in serum over several months post-STZ administration to elucidate metabolic dysfunction longitudinally in relation to sensory dysfunction. Although hyperglycemia and body weight changes occurred early, sensory loss and reduced intraepithelial branching of nociceptive nerves were only evident at 22 weeks post-STZ. The longitudinal metabolites screen in peripheral nerves demonstrated that compared with buffer-injected age-matched control mice, mice at 12 and 22 weeks post-STZ showed an early impairment the tricaoboxylic acid (TCA cycle), which is the main pathway of carbohydrate metabolism leading to energy generation. We found that levels of citric acid, ketoglutaric acid (2 KG), succinic acid, fumaric acid, and malic acid were observed to be significantly reduced in sciatic nerve at 22 weeks post-STZ. In addition, we also found the increase in levels of sorbitol and L-lactate in peripheral nerve from 12 weeks post-STZ injection. Amino acid screen in serum showed that the amino acids valine (Val), isoleucine (Ile), and leucine (Leu), grouped together as BCAA, increased more than twofold from 12 weeks post-STZ. Similarly, the levels of tyrosine (Tyr), asparagine (Asn), serine (Ser), histidine (His), alanine (Ala), and proline (Pro) showed progressive increase with progression of diabetes. Our results indicate that the impaired TCA cycle metabolites in peripheral nerve are the primary cause of shunting metabolic substrate to compensatory pathways, which leads to sensory nerve fiber loss in skin and contribute to onset and progression of peripheral neuropathy.
Identifiants
pubmed: 30949723
doi: 10.1007/s00109-019-01781-1
pii: 10.1007/s00109-019-01781-1
doi:
Substances chimiques
Amino Acids
0
Streptozocin
5W494URQ81
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
845-854Références
Diabetes. 2007 Jun;56(6):1592-9
pubmed: 17351150
Proc Natl Acad Sci U S A. 1982 Jan;79(2):630-4
pubmed: 6210909
J Endocrinol. 2013 Jan 02;216(1):1-11
pubmed: 23086140
Nature. 2001 Dec 13;414(6865):813-20
pubmed: 11742414
Diabetes. 2011 Jan;60(1):288-97
pubmed: 20876714
J Neurosci. 2000 Dec 15;20(24):8972-9
pubmed: 11124972
Am J Physiol Endocrinol Metab. 2006 Jun;290(6):E1057-67
pubmed: 16380392
Am J Transplant. 2003 Mar;3(3):267-72
pubmed: 12614280
J Mol Cell Cardiol. 2009 Jun;46(6):919-26
pubmed: 19249309
Diabetes. 2002 Oct;51(10):2944-50
pubmed: 12351431
PLoS One. 2012;7(11):e50805
pubmed: 23209829
Nat Rev Neurol. 2011 Sep 13;7(10):573-83
pubmed: 21912405
Diabetes. 2005 Jan;54(1):234-42
pubmed: 15616034
Pain Med. 2007 Sep;8 Suppl 2:S50-62
pubmed: 17714116
Toxicol Appl Pharmacol. 2006 Apr 15;212(2):167-78
pubmed: 16490224
Diabetes Care. 2013 Nov;36(11):3712-7
pubmed: 24026557
J Diabetes Res. 2016;2016:2108909
pubmed: 26881241
Pract Neurol. 2014 Dec;14(6):368-79
pubmed: 24778270
Circ Res. 2010 Oct 29;107(9):1058-70
pubmed: 21030723
Malays J Med Sci. 2011 Oct;18(4):26-31
pubmed: 22589670
Diabetes. 1992 Jul;41(7):866-71
pubmed: 1377137
J Int Soc Sports Nutr. 2017 Aug 22;14:30
pubmed: 28852372
PLoS Med. 2006 Nov;3(11):e442
pubmed: 17132052
Acta Histochem. 2008;110(5):351-62
pubmed: 18384843
Neuron. 2017 Mar 22;93(6):1296-1313
pubmed: 28334605
Free Radic Biol Med. 2006 Mar 1;40(5):886-96
pubmed: 16520240
Am J Physiol Endocrinol Metab. 2016 Jun 1;310(11):E958-69
pubmed: 27094034
J Diabetes Investig. 2011 Jan 24;2(1):18-32
pubmed: 24843457